Craif Raises $33 Million in Series D Funding
Craif, a Tokyo-based bio-AI startup, has announced the successful closure of a $33 million Series D funding round as of August 18, 2026. The round was led by Granite-Integral and Tauns Co., Ltd, with participation from investors Unreasonable and X&KSK.
Innovative Approach to Disease Detection
Founded in 2018, Craif specializes in the early detection of diseases, including cancer, by analyzing microRNA found in urine and saliva. The company uses its proprietary biomarker analysis platform, NANO IP, alongside artificial intelligence to achieve these results. Ryuichi Onose, the CEO of Craif, leads the company in its mission to advance healthcare through innovative technology.
Strategic Use of Funds
While the specific allocation of the new funds has not been detailed, it is expected that Craif will continue to enhance its technological capabilities and possibly expand its market reach. The infusion of capital will likely support the company's ongoing research and development efforts, aiming to further improve their diagnostic solutions.
Investor Confidence
The involvement of prominent investors such as Granite-Integral and Tauns Co., Ltd reflects strong confidence in Craif's potential to impact the healthcare industry significantly. With the backing of these investors, Craif is well-positioned to continue its growth and innovation in the bio-AI sector.